Valproic Acid
NDC Package 63739-253-40

11-digit billing NDC: 63739025340 · Billing unit: EA · 100 EA per package

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Valproic Acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)].Valproic acid are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].Valproic acid are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)].Valproic acid are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].For use in prophylaxis of migraine headaches: Valproic acid are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1)]. Marketed by Mckesson Corporation Dba Sky Packaging, this product is identified by NDC 63739-253 and is authorized under FDA application ANDA207611.

Identification & Billing

NDC Package Code
63739-253-40
Package Description
100 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
63739025340
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Valproic Acid
Dosage Form
-
Usage Information
Valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)].Valproic acid are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].Valproic acid are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)].Valproic acid are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].For use in prophylaxis of migraine headaches: Valproic acid are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1)].

Regulatory & Marketing

Labeler Name
Mckesson Corporation Dba Sky Packaging
FDA Application #
ANDA207611
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-21-2020
Listing Expiration
12-31-2025
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 63739-253-40 identifies a specific commercial package of 100 capsule in 1 bottle of Valproic Acid, labeled by Mckesson Corporation Dba Sky Packaging. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Mckesson Corporation Dba Sky Packaging on February 21, 2020. The current certification is valid through December 31, 2025.

How is this Mckesson Corporation Dba Sky Packaging product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 63739025340. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
63739-253-40
11-Digit CMS (5-4-2)
63739-0253-40

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.